anti-PD-1 therapy
Phase 2Small molecule
anti-PD-1 therapy is one of 3 small molecule programs targeting Advanced or Metastatic Solid Tumor Malignancies. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Advanced or Metastatic Solid Tumor Malignancies
#DrugCompanyPhaseTrials
1NP-G2-044
NNovita Pharmaceuticals, Inc.
Phase 2
anti-PD-1 therapy
NNovita Pharmaceuticals, Inc.
Phase 2
Chemotherapy Drug
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Head and Neck Squamous Cell Carcinoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for anti-PD-1 therapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- NNovita Pharmaceuticals, Inc.